JP2003527342A5 - - Google Patents

Download PDF

Info

Publication number
JP2003527342A5
JP2003527342A5 JP2001539455A JP2001539455A JP2003527342A5 JP 2003527342 A5 JP2003527342 A5 JP 2003527342A5 JP 2001539455 A JP2001539455 A JP 2001539455A JP 2001539455 A JP2001539455 A JP 2001539455A JP 2003527342 A5 JP2003527342 A5 JP 2003527342A5
Authority
JP
Japan
Prior art keywords
composition
glucocorticoid receptor
receptor antagonist
administration
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001539455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003527342A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/032260 external-priority patent/WO2001037840A1/en
Publication of JP2003527342A publication Critical patent/JP2003527342A/ja
Publication of JP2003527342A5 publication Critical patent/JP2003527342A5/ja
Pending legal-status Critical Current

Links

JP2001539455A 1999-11-23 2000-11-21 軽度認知障害を処置する方法 Pending JP2003527342A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16743299P 1999-11-23 1999-11-23
US60/167,432 1999-11-23
PCT/US2000/032260 WO2001037840A1 (en) 1999-11-23 2000-11-21 Methods for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
JP2003527342A JP2003527342A (ja) 2003-09-16
JP2003527342A5 true JP2003527342A5 (https=) 2007-11-29

Family

ID=22607362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001539455A Pending JP2003527342A (ja) 1999-11-23 2000-11-21 軽度認知障害を処置する方法

Country Status (7)

Country Link
US (2) US6620802B1 (https=)
EP (1) EP1242094A4 (https=)
JP (1) JP2003527342A (https=)
AU (1) AU778090B2 (https=)
CA (1) CA2389570C (https=)
HK (1) HK1047050A1 (https=)
WO (1) WO2001037840A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046470A1 (en) * 2000-05-10 2001-11-29 Kieko Morita Diagnoses and treatment of disorders using an alternative glucose pathway
DE60232956D1 (de) 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten
NZ531477A (en) * 2001-08-31 2006-10-27 Corcept Therapeutics Inc Use of a glucocorticoid receptor antagonist comprising a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton to decrease cognitive deterioration in adults with Down's syndrome
JP2005528395A (ja) * 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
US8237946B2 (en) * 2004-10-08 2012-08-07 Sharp Laboratories Of America, Inc. Methods and systems for imaging device accounting server redundancy
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
DK3260118T3 (da) * 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
US10500216B2 (en) 2011-11-18 2019-12-10 Corcept Therapeutics, Inc. Optimizing mifepristone absorption
US20150290158A1 (en) * 2012-11-09 2015-10-15 Elliott C. Lasser X-ray contrast media compositions and methods of using the same to treat, reduce or delay the onset of cns inflammation and inflammation associated conditions
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
US9943526B2 (en) 2015-04-21 2018-04-17 Corcept Therapeutics, Inc. Optimizing mifepristone levels for cushing's patients
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3337450A1 (de) * 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
EP0954317B1 (en) 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia

Similar Documents

Publication Publication Date Title
JP2003527342A5 (https=)
AU747956B2 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
JP2003505336A5 (https=)
JP2001518509A5 (https=)
RU99120072A (ru) Способ и композиция для профилактики и задержки начала болезни Альцгеймера
AU726091B2 (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US5747480A (en) Oral contraceptive
CA2440605A1 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
CA2454339A1 (en) Methods for preventing antipsychotic-induced weight gain
CA2389570A1 (en) Methods for treating mild cognitive impairment
JP2006508951A5 (https=)
CA2504697A1 (en) Methods for treating migraine
JP2005535664A5 (https=)
JP2006507311A5 (https=)
CA2459033A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
JPH07278017A (ja) 麻薬又は麻薬混合物からの自然の又は早められた退薬症状と関連した徴候を予防し又は治療するための薬剤の製造への抗グルココルチコイド活性を有する化合物の使用及びそれらを含有する組成物
EP0921804B1 (en) Biphasic oral contraceptive method and kit comprising a combination of a progestin and estrogen
CA2561839C (en) Multi-phase contraceptive preparation based on a natural estrogen
Baulieu A novel approach to human fertility control: contragestion by the anti-progesterone RU 486
JP2005512949A5 (https=)
CA2532594A1 (en) Antiglucocorticoids for the treatment of catatonia
CA2446506A1 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
Mazer Omalizumab reduced inhaled corticosteroid use and exacerbations in childhood allergic asthma
EP1726307A2 (en) Methods for treating psychosis associated with glucocorticoid related dysfunction
HK1022843B (en) Monophasic oral contraceptive method and kit comprising a combination of progestin and estrogen